Trials / Enrolling By Invitation
Enrolling By InvitationNCT06835244
Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms
Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms: A Monocentric Observational Experience
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to collect data from PET/CT-PSMA performed in patients with neoplasms expressing PSMA, other than prostate cancer. Objectives The primary objective is to evaluate the diagnostic performance of PET/CT-PSMA in the staging and management of patients with non-prostatic neoplasms expressing PSMA. The secondary objective is to analyze the prognostic value of PET-PSMA in such neoplasms and the possible use in the selection of patients eligible for target therapies against neovascularization (i.e. monoclonal anti-VEGF antibodies) and radiopharmaceutical treatments (i.e. 177Lu-PSMA).
Detailed description
Purpose of the register: This single-centre observational register is intended to collect data from PET/CT-PSMA performed in patients with neoplasms expressing PSMA, other than prostate cancer. Design of the register: observational, pharmacological, non-profit, prospective, monocentric. Duration of the record: The expected duration for the collection of PET/CT-PSMA examinations is 10 years. Objectives The primary objective of the following registry is to evaluate the diagnostic performance of PET/CT-PSMA in the staging and management of patients with non-prostatic neoplasms expressing PSMA. The secondary objective is to analyze the prognostic value of PET-PSMA in such neoplasms and the possible use in the selection of patients eligible for target therapies against neovascularization (i.e. monoclonal anti-VEGF antibodies) and radiopharmaceutical treatments (i.e. 177Lu-PSMA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | 68Ga-PSMA-11 | All patients with non prostatic neoplasm expressing PSMA undergo 68\[Ga\]Ga-PSMA-11-PET/CT |
Timeline
- Start date
- 2021-09-17
- Primary completion
- 2031-06-01
- Completion
- 2031-06-01
- First posted
- 2025-02-19
- Last updated
- 2025-02-19
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06835244. Inclusion in this directory is not an endorsement.